Evidence map›Paper›PMID 34254269›Full record

ArticleJournal of racial and ethnic health disparities2022

Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center.

Omar T Sims, Duong N Truong, Kaiying Wang, Pamela A Melton, Kasey Atim

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of racial and ethnic health disparities, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Omar T SimsDepartment of Social Work, College of Arts and Sciences, University of Alabama at Birmingham, Birmingham, AL, USA. sims.omar@gmail.com.ORCID http://orcid.org/0000-0002-3207-2231
Duong N TruongDepartment of Health Care Organization and Policy, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, USA.
Kaiying WangDepartment of Mathematics and Statistics, College of Arts & Sciences, Georgia State University, Atlanta, GA, USA.
Pamela A MeltonSchool of Social Work, Tulane University, New Orleans, LA, USA.
Kasey AtimSchool of Social Work, University of Alabama, Tuscaloosa, AL, USA.
Alabama Department of Public Health · USGeorgia State University · USTulane University · USUniversity of Alabama · USUniversity of Alabama at Birmingham · US

Funding

Substance Use and HIV Prevention Research in Minority Communities Training ProgramR25DA028567 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Julia Lechuga, Torsten Brian Neilands · 2009 to 2026
$5.4M
NIDA NIH HHS R25 DA028567
6 · The paper itself

Abstract

This study aimed to assess time to hepatitis C (HCV) treatment (i.e., the time between the initial clinic visit for HCV evaluation and the HCV treatment start date), to compare clinical characteristics between patients who received HCV treatment ≥ and < 6 months, and to identify predictors of longer time to HCV treatment in patients living with HCV. This study conducted a retrospective secondary analysis of patients living with HCV mono-infection and HIV/HCV co-infection who received HCV treatment with DAAs (n=214) at a HIV Clinic. Binomial logistic regression was used to identify predictors of longer time to treatment (i.e., ≥ 6 months). The median time to HCV treatment was 211 days. Compared to patients who were treated < 6 months, a higher proportion of patients who were treated ≥ 6 months had HIV/HCV co-infection (31% vs. 49%, p=0.01) and chronic kidney disease (8% vs. 18%, p=0.03). In multivariate analysis, HIV/HCV co-infection was positively associated with a longer time to HCV treatment (adjusted odds ratio, aOR=2.0, p=0.03). Time to HCV treatment disparities between African American and White American did not emerge from the analysis, but time to HCV treatment disfavored patients living with HIV/HCV co-infection. Studies are needed to identify and eliminate factors that disfavor patients living with HIV/HCV co-infection.

Indexed as

CoinfectionHepatitis CHIV InfectionsHumansOdds RatioRetrospective StudiesDAAsDisparitiesHIV/HCV co-infectionTime to HCV treatment

Identifiers

PMID34254269
PMCPMC8752646
OpenAlexW3182431293

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.